Search Results - "Brown, Sochilt"
-
1
Abstract 5630: Anti-BCMA bispecific tool therapy against VkMYC multiple myeloma is enhanced by IMiDs
Published in Cancer research (Chicago, Ill.) (15-08-2020)“…Abstract BCMA is an ideal target antigen for myeloma immunotherapy as it is specifically expressed by plasma cells and T cell-engaging, BCMA-bispecific…”
Get full text
Journal Article -
2
Chronic Lymphocytic Leukemia in African Ancestry Population Is Characterized By Increased Telomere Erosion
Published in Blood (15-11-2022)Get full text
Journal Article -
3
IMiDs Synergize with EP300 Inhibition to Disrupt the Ikzf/MYC/IRF4 Axis in Multiple Myeloma
Published in Blood (15-11-2022)Get full text
Journal Article -
4
Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature
Published in Blood (25-04-2024)“…•Individuals with MBL who have a high-risk epigenetic/immunogenetic signature show significant risk of progression to CLL requiring therapy.•The signature…”
Get full text
Journal Article -
5
Disrupting Ectopic Super-Enhancers to Treat Multiple Myeloma
Published in Blood (23-11-2021)“…Multiple myeloma (MM) is an incurable form of plasma cell cancer in which primary and secondary chromosomal translocations routinely juxtapose oncogenes to…”
Get full text
Journal Article -
6
P-177 Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma (MM)
Published in Clinical lymphoma, myeloma and leukemia (01-09-2023)Get full text
Journal Article -
7
Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL
Published in Blood advances (11-07-2023)“…•Similar mutation frequency, type, and location in TP53 between 849 patients newly diagnosed with CLL and 381 patients with HCMBL.•Having multiple TP53…”
Get full text
Journal Article -
8
Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
Published in Blood cancer discovery (08-01-2024)“…Multiple myeloma (MM) is a malignancy that is often driven by MYC and that is sustained by IRF4, which are upregulated by super-enhancers. IKZF1 and IKZF3 bind…”
Get full text
Journal Article -
9
Tumor mutational load is prognostic for progression to therapy among high-count monoclonal B-cell lymphocytosis
Published in Blood advances (14-05-2024)“…•Tumor mutational load is a strong prognostic factor for progression to therapy among individuals with HCMBL, independent of CLL-IPI.•Accounting for both…”
Get full text
Journal Article